News Article | April 28, 2017
-- Dr. Linda Papa, Director of Academic Clinical Research at Orlando Regional Medical Center and Professor at Florida State University and McGill University, will present on her team's latest results in the study and application of blood-based biomarkers in concussion management in both child and adult patients. The 7Annual Traumatic Brain Injury Conference, taking place May 24-25, 2017 in Washington, DC, will provide a platform to discuss a variety of recent discoveries in the traumatic brain injury space. For more information on the event, visit: www.tbiconference.com.The past decade of research into biomarkers have led to the discovery of two blood-based biomarkers in suspected mild TBI and concussion patients in the emergency department. Dr. Papa will present how the markers are detectable in serum in less than an hour post-concussion, and can be used to detect the difference between concussion and other injury. The biomarkers have also been shown to predict traumatic intracranial lesions on CT and neurosurgical intervention over a week post-injury.Blood-based biomarkers have the potential to be used in a variety of environments to quickly and accurately diagnose concussion and mild traumatic brain injuries. As blood tests for traumatic brain injury are being developed and private companies are commercializing TBI biomarkers for US FDA approval, this area of study will revolutionize the management of traumatic brain injuries in the near future. For more information on Dr. Papa's research, visit: http://journals.lww.com/ sportsmedarthro/ Abstract/2016/ 090... Arrowhead Publishers' annual Traumatic Brain Injury Conference provides a unique forum for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress towards better diagnosis, treatment and long-term care for TBI survivors. This conference unites researchers and clinicians from industry, academia, the military and government to present ground-breaking research in a variety of areas related to traumatic brain injury. For more information, visit: http://tbiconference.com/ home/brochure John Waslif: Managing DirectorArrowhead Publishers866-945-0263 ext firstname.lastname@example.orgRachel Donlon: Marketing AssociateArrowhead Publishers866-945-0263 ext email@example.com
News Article | May 1, 2017
Dr. Linda Papa, Director of Academic Clinical Research at Orlando Regional Medical Center and Professor at Florida State University and McGill University, will present on her team’s latest results in the study and application of blood-based biomarkers in concussion management in both child and adult patients. The 7th Annual Traumatic Brain Injury Conference, taking place May 24-25, 2017 in Washington, DC, will provide a platform to discuss a variety of recent discoveries in the traumatic brain injury space. For more information on the event, visit: http://www.tbiconference.com. The past decade of research into biomarkers have led to the discovery of two blood-based biomarkers in suspected mild TBI and concussion patients in the emergency department. Dr. Papa will present how the markers are detectable in serum in less than an hour post-concussion, and can be used to detect the difference between concussion and other injury. The biomarkers have also been shown to predict traumatic intracranial lesions on CT and neurosurgical intervention over a week post-injury. Blood-based biomarkers have the potential to be used in a variety of environments to quickly and accurately diagnose concussion and mild traumatic brain injuries. As blood tests for traumatic brain injury are being developed and private companies are commercializing TBI biomarkers for US FDA approval, this area of study will revolutionize the management of traumatic brain injuries in the near future. For more information on Dr. Papa’s research, visit: http://journals.lww.com/sportsmedarthro/Abstract/2016/09000/. Arrowhead Publishers’ annual Traumatic Brain Injury Conference provides a unique forum for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress towards better diagnosis, treatment and long-term care for TBI survivors. This conference unites researchers and clinicians from industry, academia, the military and government to present ground-breaking research in a variety of areas related to traumatic brain injury. For more information, visit: http://tbiconference.com/home/brochure. For more information, please contact: John Waslif: Managing Director Arrowhead Publishers 866-945-0263 ext 700 john.waslif(at)tbiconference(dot)com
News Article | April 26, 2017
Discover how disaster drives innovation as the healthcare of catastrophes is discussed at this year's event. -- A trio of experts will speak at the Mensa Foundation's 2017 Colloquium July 5 at the Diplomat Resort in Hollywood, Fla., this year examining the Health Care of Catastrophes. Dr. Sheri Fink, Dr. Joseph Ibrahim and Dr. Michael Osterholm will explore the complex care challenges that the medical community faces as it takes on hurricanes, mass shootings and other manmade and natural disasters.Dr. Fink's coverage of life-or-death decisions made at a Hurricane Katrina-besieged hospital won the 2010 Pulitzer Prize for investigative reporting. Her expertise on the health care of disasters extends beyond her award-winning reporting on New Orleans' Memorial Hospital. The work by Dr. Fink and hercolleagues on the 2014 West Africa Ebola crisis was recognized with the 2015 Pulitzer for international reporting.Dr. Ibrahim serves as trauma medical director at Orlando Regional Medical Center, overseeing Central Florida's only Level 1 trauma center. Ibrahim's team was key in responding and treating the victims of the worst mass shooting by a single assailant in U.S. history, the 2016 Pulse Nightclub shooting in Orlando, Fla.Dr. Osterholm, director of the Center for Infectious Disease Research and Policy, has been a national leader detailing the growing concern regarding the use of biological agents as catastrophic weapons targeting civilian populations. After 9/11, Dr. Osterholm served as Special Adviser to the secretary of the U.S. Department of Health and Human Services on issues regarding public health preparedness.Drs. Ibrahim, Fink and Osterholm will be accompanied by other experts who will discuss how working in exceptional circumstances can lead to exceptional ideas and solutions.Visitto register and learn more about Colloquium 2017, sponsored by the Mensa Education & Research Foundation.The Mensa Education & Research Foundation benefits society by inspiring and empowering intellectually gifted people. For more than 40 years the Foundation has supported the best and brightest through scholarships and awards. It encourages research and intellectual inquiry through theand its various Colloquiums. Governed by a volunteer Board of Trustees, the Mensa Foundation is a 501(c)(3) organization and is funded by American Mensa, Mensa members and other charitable donations. To learn more about the Foundation, visit mensafoundation.org.
News Article | December 13, 2016
Brightbox, Inc., the American B2B kiosk technology company and leading global provider of secure cell phone charging products, today announced the deployment of its platform-supported charging solution in partnership with a host of American collegiate properties and Frontier Communications Corporation. Fans can now stay powered up and connected during their stadium and arena sports experiences by charging their mobile devices in Brightbox’s highly secure charging stations. Frontier Communications branded Brightbox mobile device charging kiosks are now available for refreshing recharging experiences in football stadiums and basketball arenas across the nation, including: IMG facilitated the three-year partnership between Frontier Communications, a leading national provider of high-speed-internet, phone & TV, and Brightbox. Frontier’s branded Brightbox charging stations will now be in numerous college football and basketball facilities encouraging customers to “Charge While You Cheer.” “We are thrilled to support these great institutions of higher learning and meet the mobile power needs of their fans and students,” said Billy Gridley, CEO of Brightbox. “In a world where nearly everyone is always on-line, particularly students using mobile devices as a “second screen”, and there is no off-line, Brightbox secure charging is critical physical infrastructure and in-stadium technology that fulfills customer need, while providing global organizations with a powerful branding and marketing tool.” Brightbox is unique because it offers organizations and marketers a trifecta solution: secure mobile re-charging, digital signage and interactive features, such as data surveys, SMS messaging and product coupon delivery. Unlike other providers in the market, the Brightbox platform is open for management of a network of connected, out-of-home charging kiosks. Partners and clients can access the Brightbox platform to directly manage their own video content and messaging, download reporting data and analytics, remotely support their fleet, and conduct marketing and lead capture campaigns. As the global technology leader in the field, Brightbox offers a breadth of locker key choices: secure masked on-screen pin code, mag stripe cards (financial, customized and loyalty) and RFID. Brightbox was the first secure charging solution on the market to offer USB-C charging support for the latest generation of smartphones. Brightbox is committed to delivering secure, safe and reliable power for mobile users when they need it most, with a hardened LINUX-based connected platform solution and kiosk product offerings that are the most innovative and sophisticated in the marketplace. About Brightbox Brightbox® is a B2B kiosk technology company providing venues with a best-in-class mobile device recharging and digital marketing platform. Founded in 2011, Brightbox delivers advanced and innovative solutions, and has deployed over 800 secure recharging kiosks in 10 countries and 22 American states and 4 Canadian Provinces in a variety of vertical markets including retail, entertainment, hospitality, events, healthcare, transport and government. Enterprise customers include AOL, American Airlines, Baystate Health, Cadillac Fairview, Caesars Entertainment, Christie’s, Citibank, Comcast, Coca-Coca Company, Columbia University, CUNY, Dream, Fifth Third Bank, Grand Bazaar Shops, HBO, Hilton, Honda, Hyatt, IBM, IMG College, Intel, JC Penney, MGM, Memorial City Mall, Mount Sinai Health, New York Red Bulls, Newad, Omni, Orlando Regional Medical Center, Phoenix Suns, Planet Hollywood, Samsung, SeaWorld, Sheraton, Spectrum, Statue of Liberty, T-Mobile, Wells Fargo, Westfield Malls, Wynn Resorts and Yale New Haven Health. Brightbox has technology and operator partners in the US, Brazil, Canada, Chile, Europe, Mexico, Panama, South Africa, Sweden and the United Kingdom. Learn more at https://brightboxcharge.com/ @brightboxcharge About Frontier Communications Corporation Frontier Communications Corporation is a leader in providing communications services to urban, suburban, and rural communities in 29 states. Frontier offers a variety of services to residential customers over its fiber-optic and copper networks, including video, high-speed internet, advanced voice, and Frontier Secure ® digital protection solutions. Frontier Business Edge™ offers communications solutions to small, medium, and enterprise businesses.
News Article | March 30, 2016
New research bolsters evidence that a simple blood test may someday be used to detect concussions. It suggests that a protein linked with head trauma may be present in blood up to a week after injury, which could help diagnose patients who delay seeking treatment. The study involved patients at one hospital in Florida and the results are preliminary - a concussion blood test based on the two proteins studied or on other so-called biomarkers under review is likely at least a few years away from routine use. But the new findings "are a substantial step" in developing a test that could be used in broad settings, from the battlefield to sports events and doctors' offices. That's according to an editorial published with the study Monday in JAMA Neurology. Dr. Ramon Diaz-Arrastia, co-author of the editorial and a researcher at the government's Uniformed Services University of the Health Sciences, said it's likely that several biomarkers will be found to be useful for diagnosing concussions, "each of which will tell us something slightly different" about the injury. Dr. Linda Papa, an Orlando Health emergency medicine specialist and colleagues tested nearly 600 adults treated at Orlando Regional Medical Center. About half had concussions from car crashes, falls, sports and other activities. Most were mild, with symptoms that included loss of consciousness, amnesia or feeling disoriented. The rest of the adults had fractures or other types of non-brain trauma. Blood samples were taken starting four hours following the injury, then periodically for seven days. The tests measured two proteins nicknamed GFAP and UCH-L1, which are present in brain cells. In a head injury, the proteins can leak into the bloodstream, Papa said. Other research has shown blood levels of the proteins are highest with the most severe injuries. In this study, levels of both proteins were much higher in concussion patients. The proteins were found in low levels in some non-concussion patients, probably from a head bump or jostling during an accident but not true concussions, Papa said. Levels of the UCH protein rose quickly but declined substantially within two days, while GFAP levels were detectable during the week following injury. Many concussion patients put off going to the doctor because they think the injury isn't serious, but end up seeking treatment a few days later when symptoms persist, Papa said. She said blood tests could help diagnose these patients, and could help determine whether neurological testing or other medical treatment is needed. Typically doctors advise rest from work, school and other taxing activities until after concussion symptoms have disappeared. Dr. Walter Koroshetz, director of the National Institute of Neurological Disorders and Stroke, called the data encouraging and said finding an easily detectable biomarker for concussions is "the holy grail for head injury" research. His agency paid for the study and the U.S. government has spent millions of dollars on concussion research. More than 2 million people nationwide get emergency room treatment for concussions and other brain trauma each year. Damage may not be visible on imaging tests so doctors typically rely on symptoms. Diagnosis is important because repeated head blows have been linked with lasting memory problems and potentially a degenerative brain disease found in some retired NFL players. Southern Illinois University neuroscientist Michael Hylin noted that some concussion symptoms, including dizziness and fatique, can also be caused by dehydration, which is another threat to athletes involved in rigorous sports. A test that could distinguish between the two conditions would be useful to help guide treatment, he said. Papa noted that there are blood tests to diagnose problems with other organs, including the heart, liver and kidneys, "and now we're really coming close to having something for the brain." She is an unpaid scientific consultant for Banyan Biomarkers, Inc. The Florida company announced earlier this year that is working with Royal Philips to develop a hand-held device that would analyze blood samples and display results within minutes showing if the proteins are present.
Adigweme O.O.,Orlando Regional Medical Center
The journal of knee surgery | Year: 2013
Periprosthetic patellar fractures represent a spectrum of injuries to a patient with a total knee arthroplasty. They range in severity from an inconsequential injury, which does not compromise function, to a severely debilitating injury that may require advanced reconstructive measures. This article will outline the epidemiology and risk factors associated with periprosthetic patellar fractures. Treatment options as they relate to injury mechanism, fracture severity, patellar component stability, and remaining bone stock will also be discussed. Finally, a review of the current literature regarding the results of treatment will be presented. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Haidukewych G.J.,Orlando Regional Medical Center |
Hanssen A.,Mayo Medical School
Journal of the American Academy of Orthopaedic Surgeons | Year: 2011
The need for revision total knee arthroplasty (TKA) is on the rise. Challenges to attaining durable, stable, well-functioning revision TKA include bony deficiency, periarticular osteopenia, deformity, and soft-tissue imbalance. Defect management often requires the use of stems, cement, metal augmentation, or allograft. Recently, there has been interest in obtaining fixation in the metaphyseal region in an attempt to improve construct stability while managing bony deficiency. Often, the metaphyseal bone is well vascularized, which provides an opportunity for additional fixation with cement, allograft, trabecular metal cones, or stepped porous-coated sleeves. Multiple series have documented good survivorship at short-term follow-up with trabecular metal cones and porous-coated sleeves. These newer technologies offer biologic fixation and are useful for treating bony defects that are not easily managed with other methods. Long-term studies are needed to determine the durability of these constructs. Concerns persist regarding stress shielding and difficulty of removal. Familiarity with the rationale and strategies for metaphyseal fixation in revision TKA is a valuable addition to the armamentarium of the revision surgeon. Copyright 2011 by the American Academy of Orthopaedic Surgeons.
Lube M.W.,Orlando Regional Medical Center
Journal of surgical education | Year: 2010
OBJECTIVE: To evaluate the effectiveness of a new basic science curriculum at a university-affiliated general surgery residency program. DESIGN: A retrospective evaluation of general surgery residents' American Board of Surgery (ABS) In-Training Examination (ABSITE) scores before and after the implementation of a new basic science curriculum. SETTING: Not-for-profit tertiary referral center with a university-affiliated Accreditation Council for Graduate Medical Education (ACGME) accredited community general surgery residency program. PARTICIPANTS: Postgraduate year (PGY) 1 through 5 general surgical residents. RESULTS: The total questions answered correctly (percent correct) in the main 3 categories improved after implementation of the new curriculum for PGY 1 (total test: 70 +/- 7 vs 60 +/- 9, p < 0.05; clinical science: 71 +/- 10 vs 59 +/- 9, p < 0.05; and basic science: 69 +/- 7 vs 60 +/- 10, p = 0.0003) and for PGY 2 residents (total test: 74 +/- 5 vs 66 +/- 7, p < 0.05; clinical science: 74 +/- 7 vs 66 +/- 8, p = 0.003; and basic science: 74 +/- 5 vs 66 +/- 8, p < 0.05). With the exception of the percentage of clinical questions answered correctly for the PGY 4 level, there was no statistically significant worsening of scores in any other subcategories for any other PGY levels (3 through 5) after implementation of the new program. Before the institution of the new curriculum, 24% (26/110) of residents scored below the 35th percentile, and after the institution of the new curriculum, this number decreased to 12% (12/98), p = 0.006. The first-time passage rate on the ABS Qualifying Examination was unchanged in the period before and after the implementation of the new curriculum (89% vs 86%; p = 0.08). When comparing the bimonthly quizzes with the ABSITE, the correlation coefficient was 0.34. CONCLUSION: After the implementation of a new basic science curriculum organized and directed by the faculty, there were statistically significant improvements of PGY 1 and 2 residents' ABSITE scores. Copyright (c) 2010 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved.
Petrie J.,Orlando Regional Medical Center
The journal of knee surgery | Year: 2013
Open reduction and internal fixation (ORIF) of patellar fractures generally leads to good results; however, the potential for surgical complications exists. Nonunion, infection, posttraumatic arthritis, arthrofibrosis, symptomatic hardware, and extensor mechanism insufficiency have all been described following patellar ORIF, and the risk of their occurrence may be augmented by patient-, injury-, and treatment-related factors. When complications arise, advanced reconstructive techniques are often required for successful management. This review will report the incidence of the aforementioned complications, highlight risk factors contributing to their frequency, discuss treatment options, and present the reported results of selected treatment strategies from available literature. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
News Article | November 29, 2016
ClassAction.com attorney Mike Morgan has filed a product liability and negligence lawsuit against e-cigarette manufacturers and retailers over an alleged vape explosion that he says injured his clients, Florida couple James Dardini and Angela Dardini. Mr. and Mrs. Dardini’s complaint was filed in the Seventh Judicial Circuit in and for Volusia County, Florida, on September 16, 2016. Defendants include Kangertech, which allegedly made the vape devices; Sunshine Vapor, the retailer that allegedly sold Mr. Dardini the vape products; and Perfect Vape, which allegedly imported the devices and sold them to Sunshine Vapor. The lawsuit seeks damages, costs, interest, and attorney fees, plus any further relief that the Court deems just and proper. The complaint alleges strict liability, negligence, design and manufacturing failures and failure to adequately warn plaintiffs of the products’ risks, among other charges. The complaint states that Mr. Dardini purchased a Kanger vaporizer and battery from the Sunshine store on September 21, 2015. On December 28, 2015, while at work in Ocoee, Florida, Mr. Dardini alleges that around 11am—a few hours after allegedly using the device on his way to work—the vaporizer device exploded in his front right pocket, “engulfing Mr. Dardini’s leg in flames.” The complaint alleges that Mr. Dardini had to be transported to Health First Hospital in Clermont, Florida, before then being transferred to the Burn Unit at Orlando Regional Medical Center (ORMC) to be treated for second and third degree burns. While at ORMC, the complaint claims that Mr. Dardini had to undergo “a significant skin graft surgery to his right leg.” As a result of this alleged incident, the complaint states, “Mr. Dardini sustained severe, permanent and life-altering injuries to his groin, legs and lower back.” The complaint continues by claiming these allegations: As a direct and proximate cause of the foregoing conduct of Defendant Perfect Vape [and Sunshine, and Kangertech], Mr. Dardini sustained serious and permanent bodily injuries resulting in pain and suffering, permanent impairment, disability, mental anguish, inconvenience, loss of the enjoyment of life, expense of medical care and treatment, expense of hospitalization, lost wages in the past and the loss of ability to earn wages in the future. Mr. Dardini’s wife Angela is a plaintiff because the lawsuit claims that Mr. Dardini’s alleged injuries have affected their marriage and caused Mrs. Dardini “loss of affection” and “mental anguish.” The complaint alleges: …as a direct and proximate result of the foregoing, Mrs. Dardini suffered the following damages: (1) loss of consortium and damage to her husband/wife relationship; (2) loss of affection, solace, comfort, companionship, society, assistance, sexual relations, emotional support and love; and (3) mental anguish. The complaint includes photos of the alleged injuries and vape devices in question. ClassAction.com is part of the Complex Litigation branch of nationwide plaintiff’s law firm Morgan & Morgan. Mike Morgan is the managing partner of Morgan & Morgan’s Product Safety Group, which represents individuals who have been injured due to poorly designed and defective products. CIRCUIT COURT OF THE SEVENTH JUDICIAL CIRCUIT IN AND FOR VOLUSIA COUNTY, FLORIDA JAMES DARDINI and ANGELA DARDINI, Plaintiffs vs. SUNSHINE VAPOR, LLC, Florida Limited Liability Company; KANGERTECH U.S., LLC, a Georgia Limited Liability Company; KANGERTECH US DISTRIBUTIONS LLC, a Georgia Limited Liability Company; KANGERTECH HOLDINGS LLC, a Georgia Limited Liability Company; and PERFECT VAPE, LLC, an Oklahoma Limited Liability Company; Defendants CASE NUMBER: 201610220CIDL E-Filed: 09/16/2016